BioCentury
ARTICLE | Clinical News

Maribavir: Additional Phase II data

March 2, 2015 8:00 AM UTC

Shire disclosed in its 2014 earnings that additional data from a double-blind, U.S. Phase II trial in about 120 transplant recipients ages >=12 with resistant or refractory CMV infection showed that twice-daily 400, 800 and 1,200 mg oral maribavir led to undetectable plasma CMV DNA in about two-thirds of patients within 6 weeks. Interim data from 13 patients in the trial were reported in 2013 (see BioCentury, May 6, 2013). ...